

POSTER PRESENTATION

Open Access

# Dual targeting of the tumor and its associated vasculature using a single bispecific chimeric antigen receptor molecule

Tiara Byrd<sup>1\*</sup>, Kristen Fousek<sup>1</sup>, Antonella Pignata<sup>1</sup>, Amanda Wakefield<sup>1</sup>, Zakaria Grada<sup>2</sup>, Kevin Aviles-Padilla<sup>1</sup>, Bradley S Fletcher<sup>3</sup>, Meenakshi Hegde<sup>1</sup>, Brad St Croix<sup>4</sup>, Nabil Ahmed<sup>1</sup>

From Society for Immunotherapy of Cancer 29th Annual Meeting  
National Harbor, MD, USA. 6-9 November 2014

## Background

We have previously demonstrated the efficacy of HER2 specific chimeric antigen receptor (CAR) T cells in animal models of human cancer. While HER2 CAR T cells induced tumor regression, tumors recurred in a subset of animals. Lytic co-targeting of the tumor endothelium could represent a strategy that enhances tumor control. Tumor endothelium marker 8 (TEM8) is a recently described tumor endothelium-restricted antigen conserved in both mice and humans that represents an attractive antigen for vascular targeting [1].

## Purpose

To test the advantage of co-targeting TEM8 in conjunction with HER2 using a T cell product expressing a novel TEM8/HER2 bispecific CAR molecule.

## Methods

We designed, *in silico*, a single CAR molecule with both TEM8 and HER2-specific exodomains joined together in tandem (thus termed TanCAR). A retroviral construct encoding a TEM8 specific single chain variable fragment (scFv) from the mAb SB5, a Glycine/Serine linker and a HER2 specific scFv (mAb FRP5) exodomain, followed by a CD28 transmembrane domain, and a CD28.CD3-zeta signaling endodomain was transduced CD3/CD28-activated T cells with RD114-pseudotyped retroviral particles to generate TEM8/HER2 bispecific TanCAR T cells. CAR expression was confirmed by flow cytometry. Standard immunoassays were used to test the CAR T cell functionality.

## Results

TEM8/HER2 TanCAR molecules were expressed on the surface of up to 90% of primary T cells. Staining specific for FRP5 and SB5 ensured the expression of the TanCAR molecule in its entirety. TanCAR T cells selectively recognized and killed TEM8 and HER2 positive targets distinctly, as evidenced by the release of the immunostimulatory cytokines interferon-gamma and interleukin-2 *in vitro* and standard 4 hour <sup>51</sup>Cr release cytotoxicity assays. Cytokine release and killing were significantly enhanced when TanCAR T cells encountered both target antigens simultaneously. The kinetics of T cell activation followed a second order kinetic equation denoting a superadditive or synergistic effect upon recognition of a second antigen. Minimal activation or cytolytic activity occurred with target negative controls or with CAR null T cells.

## Conclusion

Co-targeting the tumor and its vasculature using bispecific TanCAR T cells could enhance activation of these cells and potentially be used to improve tumor control with therapeutic application in cancer patients.

## Authors' details

<sup>1</sup>Baylor College of Medicine, Houston, TX, USA. <sup>2</sup>Brown University, Providence, RI, USA. <sup>3</sup>University of Florida, Gainesville, FL, USA. <sup>4</sup>National Cancer Institute, Frederick, MD, USA.

Published: 6 November 2014

<sup>1</sup>Baylor College of Medicine, Houston, TX, USA  
Full list of author information is available at the end of the article

#### Reference

1. Chaudhary A, Hilton MB, Seaman S, Haines DC, Stevenson S, Lemotte PK, Tschantz WR, Zhang XM, Saha S, Fleming T, St Croix B: **TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types.** *Cancer Cell* 2012, **21**(2):212-26.

doi:10.1186/2051-1426-2-S3-P6

**Cite this article as:** Byrd *et al.*: Dual targeting of the tumor and its associated vasculature using a single bispecific chimeric antigen receptor molecule. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P6.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

